Health Trials

A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

ConditionSevere Asthma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorKinaset Therapeutics Inc

About this trial

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Frevecitinib
  • Placebo

Treatment groups

512 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Kinaset Therapeutics Inc

Lead sponsor

Source ClinicalTrials.gov